Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
Novel therapies for the treatment of CLL, MCL and FL
Treatment landscape for high-risk multiple myeloma patients
Patient-physician communication: an important contributor to cancer care